

Date : 5<sup>th</sup> November, 2019.

To  
BSE Ltd.  
P.J. Towers, Dalal Street,  
**Mumbai - 400 001.**

Sub.: **Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Reg.: **Outcome of Board Meeting held today, i.e. 5<sup>th</sup> November, 2019.**


Dear Sir,

1. The Unaudited Financial Statments for the quarter and half year ended on 30<sup>th</sup> September, 2019 have been approved and adopted by the Board, on the recommendation of Audit Committee, vide their meeting held on even date. The same has been attached herewith in the format required under Regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, alongwith statement of Cash Flow and Assets & Liabilities for the half year ended on 30<sup>th</sup> September, 2019.
2. The Limited Audit Review Report of Auditors of the Company, on the unaudited financial results for the quarter ended on 30<sup>th</sup> September, 2019, is also attached.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,  
For Jenburkt Pharmaceuticals Ltd.,



(ASHISH SHAH)  
Company Secretary.

Encl.: As stated above.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 



**Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended on 30/09/2019**

(Rs. In Lacs other than EPS)

| Sr. No. | Particulars   | Quarter Ended |            |            | Year to Date |            | Year Ended |
|---------|---|---------------|------------|------------|--------------|------------|------------|
|         |   | 30/09/2019    | 30/06/2019 | 30/09/2018 | 30/09/2019   | 30/09/2018 | 31/03/2019 |
|         |   | Unaudited     | Unaudited  | Unaudited  | Unaudited    | Unaudited  | Audited    |
| 1       | Revenue from Operations   | 3418.13       | 2083.74    | 3198.44    | 5501.87      | 5524.26    | 12264.43   |
| 2       | Other Income  | 85.95         | 123.80     | 90.48      | 209.75       | 181.01     | 340.97     |
| 3       | Total income  | 3504.08       | 2207.54    | 3288.92    | 5711.62      | 5705.27    | 12605.40   |
| 4       | Expenses  |               |            |            |              |            |            |
|         | (a) Cost of Materials Consumed  | 246.44        | 239.98     | 225.53     | 486.42       | 474.49     | 1184.31    |
|         | (b) Purchase of Stock-in-trade  | 660.87        | 644.05     | 688.03     | 1304.92      | 1256.77    | 2690.71    |
|         | (c) Changes in inventories of Finished Goods, Stock-in-trade and WIP              | 56.64         | -211.62    | 77.9       | -154.98      | -30.28     | -249.39    |
|         | (d) Employee benefit expenses   | 913.62        | 882.29     | 725.58     | 1795.91      | 1504.08    | 3120.49    |
|         | (e) Finance Costs   | 19.32         | 6.74       | 9.28       | 26.06        | 18.27      | 38.59      |
|         | (f) Depreciation and Amortisation Expense   | 53.72         | 52.84      | 33.21      | 106.56       | 64.83      | 135.30     |
|         | (g) Other expenses  | 798.06        | 591.00     | 773.12     | 1389.06      | 1350.49    | 3022.05    |
|         | Total Expenses  | 2748.67       | 2205.28    | 2532.65    | 4953.95      | 4638.65    | 9942.06    |
| 5       | Profit before exceptional items & Tax   | 755.41        | 2.26       | 756.27     | 757.67       | 1066.62    | 2663.34    |
| 6       | Exceptional Items   | 0.00          | 0.00       | 0.00       | 0.00         | 0.00       | 0.00       |
| 7       | Profit before tax   | 755.41        | 2.26       | 756.27     | 757.67       | 1066.62    | 2663.34    |
| 8       | Tax Expense   |               |            |            |              |            |            |
|         | (i) Current Tax   | 200.00        | 0.00       | 195.00     | 200.00       | 300.00     | 752.00     |
|         | (ii) Income Tax for previous years  | 1.79          | 0.00       | 0.00       | 1.79         | -32.80     | -37.52     |
|         | (ii) Deferred Tax   | -1.63         | -3.93      | -13.11     | -5.56        | -44.67     | -30.92     |
| 9       | Profit after tax for the period   | 555.25        | 6.19       | 574.38     | 561.44       | 844.09     | 1979.78    |
| 10      | Other Comprehensive Income  |               |            |            |              |            |            |
|         | (i) Items that will not be reclassified to profit or loss                         | -6.78         | 9.41       | 0.00       | 2.63         | 0.00       | -44.97     |
|         | (ii) Income Tax relating to Items that will not be reclassified to profit or loss | -19.18        | 19.18      | 0.00       | 0.00         | 0.00       | 17.68      |
|         | (iii) Items that will be reclassified to profit or loss                           | 0.00          | 0.00       | -7.67      | 0.00         | -0.14      | 0.00       |
|         | (iv) Income Tax relating to Items that will be reclassified to profit or loss     | 0.00          | 0.00       | 1.43       | 0.00         | -10.68     | 0.00       |
| 11      | Total Comprehensive Income for the period   | 529.29        | 34.78      | 568.14     | 564.07       | 833.27     | 1952.49    |
| 12      | Paid up Equity Share Capital (F.V. Rs.10/- each)                                  | 458.94        | 458.94     | 458.94     | 458.94       | 458.94     | 458.94     |
| 13      | Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted                      | 12.10         | 0.13       | 12.52      | 12.23        | 18.39      | 43.14      |

**Notes:**

- The above statement of unaudited standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 5<sup>th</sup> November, 2019.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The figures of the previous year/period have been regrouped/rearranged to render them comparable with figures of the current period.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 



- 4 In the current year from 1<sup>st</sup> April 2019 the company has changed the method of valuation of finished goods and work in progress from batch costing method to weighted average cost method. Thus the own-manufactured stock for the period ended 30<sup>th</sup> September 2019 is stated at weighted average cost, whereas the corresponding stock for the previous year is valued as per batch costing method. The financial impact of the change in method of stock valuation from batch costing method to weighted average method for the period ended 30<sup>th</sup> September 2019 is as follows :

|   |        |
|---|--------|
| Inventory of Own Manufactured Goods under Batch Costing Method    | 252.65 |
| Effect of decrease in Cost Of Goods Sold                          | 2.84   |
| Inventory of Own Manufactured Goods under Weighted Average Method | 255.50 |
| Retained earning under Batch Costing Method                       | 754.82 |
| Increase in Retained earnings                                     | 2.84   |
| Retained earnings under Weighted Average Method                   | 757.67 |
| Tax Payable under Batch Costing Method                            | 199.27 |
| Increase in Income Taxes  | 0.73   |
| Tax Payable under Weighted Average Method                         | 200.00 |

- 5 Statement of Assets and Liabilities as at 30.09.2019 is as per Annexure - A, attached.  
6 Cashflow statement as at 30.09.2019 is as per Annexure - B, attached.

Place : Mumbai  
Date : 5<sup>th</sup> November, 2019

By order of the Board  
For Jenburkt Pharmaceuticals Ltd.

  
(ASHISH U BHUTA)  
CHAIRMAN AND MANAGING DIRECTOR  


 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 



| Annexure - A                                   |   |                  |                  |  |
|--|---|------------------|------------------|--|
| Standalone Statement of Assets and Liabilities |   |                  |                  |  |
| (Rs. In Lacs)                                  |   |                  |                  |  |
| Sr. No.  | Particulars   | AS AT 30/09/2019 | AS AT 31/03/2019 |  |
|  |   | Unaudited        | Audited          |  |
| (A)  | <b>ASSETS</b>   |                  |                  |  |
| (1)  | <b>Non Current Assets</b>   |                  |                  |  |
| (a)  | Property, Plants & Equipments   | 893.33           | 943.16           |  |
| (b)  | Goodwill  | 0.14             | 0.14             |  |
| (c)  | Other Intangible assets   | 282.18           | 15.89            |  |
| (d)  | Capital Work In Progress  | 0.00             | 99.00            |  |
| (e)  | Financial Assets  |                  |                  |  |
| (i)  | Investments   | 194.42           | 185.61           |  |
| (ii)   | Loans   | 0.00             | 16.78            |  |
| (f)  | Deferred tax assets (Net)   | 42.38            | 36.81            |  |
| (g)  | Other non-current assets  | 0.00             | 18.31            |  |
| (2)  | <b>Current assets</b>   |                  |                  |  |
| (a)  | Inventories   | 1146.27          | 983.12           |  |
| (b)  | Financial Assets  |                  |                  |  |
| (i)  | Investments   | 346.40           | 352.10           |  |
| (ii)   | Trade receivables   | 1708.78          | 2289.49          |  |
| (iii)  | Cash and cash equivalents   | 192.22           | 122.68           |  |
| (iv)   | Bank balance other than (iii)   | 5025.18          | 5047.33          |  |
| (v)  | Loans   | 46.15            | 31.64            |  |
| (vi)   | Others  | 48.12            | 59.80            |  |
| (c)  | Other current assets  | 113.48           | 80.63            |  |
| (d)  | Current tax Assets (Net)  | 125.27           | 0.00             |  |
|  | <b>Total Assets</b>   | <b>10,164.32</b> | <b>10,282.49</b> |  |
| (B)  | <b>EQUITY AND LIABILITIES</b>   |                  |                  |  |
|  | <b>Equity</b>   |                  |                  |  |
| (a)  | Equity Share capital  | 458.94           | 458.94           |  |
| (b)  | Other Equity - Reserves & Surplus   | 7287.36          | 7287.61          |  |
|  | <b>LIABILITIES</b>  |                  |                  |  |
| (1)  | <b>Non current liabilities</b>  |                  |                  |  |
| (a)  | Financial Liabilities - Borrowings  | 0.00             | 0.00             |  |
| (b)  | Other non-current liabilities   | 281.38           | 274.38           |  |
| (2)  | <b>Current Liabilities</b>  |                  |                  |  |
| (a)  | Financial Liabilities   |                  |                  |  |
| (i)  | Borrowings  | 477.50           | 746.94           |  |
| (ii)   | Trade payables  |                  |                  |  |
|  | Total outstanding dues of Micro Enterprises and Small Enterprises; and                  | 0.00             | 21.49            |  |
|  | Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises. | 680.16           | 633.40           |  |
| (iii)  | Other financial liabilities   | 523.88           | 626.92           |  |
| (b)  | Other current liabilities   | 413.57           | 177.86           |  |
| (c)  | Provisions  | 41.53            | 41.52            |  |
| (d)  | Current tax liabilities (Net)   | 0.00             | 13.43            |  |
|  | <b>Total Equity and Liabilities</b>   | <b>10,164.32</b> | <b>10,282.49</b> |  |

Place : Mumbai

Date: 5<sup>th</sup> November, 2019

By order of the Board of  
Jenburkt Pharmaceuticals Ltd.


  
Ashish U. Bhuta  
Chairman & Managing Director



**Annexure - B**
**Cash Flow Statement as at 31/03/2019**

|           |   | AS AT 30/09/2019 | AS AT 31/03/2019  |
|-----------|---|------------------|-------------------|
|           |   | Unaudited        | Audited           |
| <b>A.</b> | <b>CASH FLOW FROM OPERATING ACTIVITIES :</b>  |                  |                   |
| a         | Net Profit before tax   | 757.67           | 2663.34           |
|           | Adjustments for :   |                  |                   |
| i         | Depreciation and Amortisation Expense   | 106.56           | 135.31            |
| ii        | Profit on sale/written off of property, plant and equipment and intangible assets, net  | 0.00             | 3.48              |
| iii       | Finance Cost  | 26.06            | 38.59             |
| iv        | Interest Income   | -169.60          | -320.50           |
| v         | Dividend income   | -3.07            | -23.37            |
| vi        | Gain on sale of Investment (Short/Long Term Capital Gain)   | 0.02             | 0.00              |
| vii       | Provision/write off for doubtful trade receivables/advances   | 0.00             | 0.34              |
| viii      | Net unrealised foreign exchange gain  | -19.95           | 1.28              |
|           | <b>Operating profit (Loss) before working capital changes</b>   | <b>697.69</b>    | <b>2,498.47</b>   |
| b         | <b>MOVEMENTS IN WORKING CAPITAL</b>   |                  |                   |
| i         | Increase or (Decrease) in Inventories   | -163.16          | -302.68           |
| ii        | Increase or (Decrease) in Trade Receivables   | 580.71           | -1036.05          |
| iii       | Increase or (Decrease) in Other (Current & Non Current) Assets  | -2.86            | 5.26              |
| iv        | Increase or (Decrease) in Trade Payables  | 25.27            | 242.69            |
| v         | Increase or (Decrease) in Bank Borrowings   | -269.43          | 723.34            |
| vi        | Increase or (Decrease) in Other (Current & Non Current) Liabilities   | 159.62           | -67.87            |
| vii       | Increase or (Decrease) in Provisions  | 2.63             | -54.80            |
| c         | <b>Cash used in operation</b>   | <b>1,030.47</b>  | <b>2,008.37</b>   |
| i         | Income Taxes paid   | -340.49          | -709.68           |
|           | <b>Net cash used in operating activities (A)</b>  | <b>689.98</b>    | <b>1,298.69</b>   |
| <b>B.</b> | <b>CASH FLOW FROM INVESTING ACTIVITIES :</b>  |                  |                   |
| i         | Payments for purchase of Property, Plant and Equipment (Including Capital Work in Progress, Intangible Assets and Intangible Assets in Development) | -323.12          | -240.14           |
|           |   | 0.00             | 0.00              |
| ii        | Proceeds from disposal of property, plant and equipment and intangible assets   | 99.10            | 0.00              |
| iii       | Purchase of Investments   | -3.10            | -5010.66          |
| iv        | Proceeds from Sale / Redemption of Investments  | 0.00             | 5047.29           |
| v         | Other Bank balances not considered as cash and cash equivalents   | 0.00             | 0.00              |
|           | Bank Fixed Deposit made during the year   | -4344.90         | -3750.25          |
|           | Bank Fixed Deposit matured during the year  | 4381.20          | 2611.36           |
| vi        | Current & Non Current Financial Loans (Net employee loans given / recovered)  | 2.26             | -9.27             |
| vii       | Interest Received   | 164.35           | 275.68            |
| viii      | Dividend Received   | 3.07             | 23.37             |
|           | <b>Net cash generated by investing activities (B)</b>   | <b>(21.14)</b>   | <b>(1,052.63)</b> |
| <b>C.</b> | <b>CASH FLOW FROM FINANCING ACTIVITIES :</b>  |                  |                   |
| i         | Borrowings - Others   | 0.00             | -0.53             |
| ii        | Finance Cost  | -26.06           | -38.59            |
| iii       | Dividend paid   | -477.02          | -146.00           |
| iv        | Tax on Dividend paid  | -96.22           | -56.61            |
| v         | Payment towards Buyback with premium  | 0.00             | 0.00              |
|           | <b>Net cash used in financing activities (C)</b>  | <b>(599.30)</b>  | <b>(241.73)</b>   |
|           | <b>NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C)</b>  | <b>69.54</b>     | <b>4.31</b>       |
|           | Cash and cash equivalent at the beginning of the year (1st April, 2019)   | 122.68           | 118.37            |
|           | Cash and cash equivalent as at the end of the year (30th Sept, 2019)  | 192.22           | 122.68            |
|           |   | <b>69.54</b>     | <b>4.31</b>       |

For and on behalf of the Board of Directors of  
Jenburkt Pharmaceuticals Ltd.



Ashish U. Bhuta

Chairman & Managing Director

Place : Mumbai,

Date : 5<sup>th</sup> November, 2019

103



# D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9<sup>TH</sup> FLOOR, TARDEO CIRCLE, MUMBAI - 400034. TEL: 23513758 /  
23520330, 9322508373

Email ID: [info@drmehta.in](mailto:info@drmehta.in), [vikram@drmehta.in](mailto:vikram@drmehta.in), [ashok@drmehta.in](mailto:ashok@drmehta.in)

Limited Review report to

The Board of Directors

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of JENBURKT PHARMACEUTICALS LTD for the period 1<sup>st</sup> July 2019 to 30<sup>TH</sup> September 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity"; issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,  
Chartered Accountants  
(Firm Reg. No. 106207W)



Partner  
Vikram Mehta  
(Membership No. 047347)

UDIN: 19047347AAAAEW1893

Place: Mumbai

Date: 5<sup>TH</sup> NOVEMBER 2019